Xilio Therapeutics, a clinical-stage biotech company specializing in masked immuno-oncology therapies, announced it will present at the Stifel 2026 Healthcare Conference on November 10, 2026. The presentation will be webcast live and available for replay on the company's investor website. Xilio focuses on developing cancer treatments that activate selectively in tumors to reduce side effects. This event offers investors insight into the company's progress and future plans in cancer therapy development.
Xilio Therapeutics' upcoming presentation at the Stifel 2026 Healthcare Conference provides context for readers interested in healthcare sector dynamics. For readers following healthcare stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: Out of 150 priced health-sector US stocks tradable on Pluang, 92 rose and 55 fell today. Notable movers include TNGX (Tango Therapeutics Inc.) at USD 23.17 with a 6.48% increase and a typical hold time of 4 days, TXG (10X Genomics Inc) at USD 65.43 up 6.17% with 40% sell / 60% buy order activity and a 92-day hold time, and BTSG (BrightSpring Health Services Inc.) at USD 69.88 rising 5.46% with 100% buy order activity and a 4-day typical hold time.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
JELD-WEN Holding, Inc. reported a net loss of $17.2 million in Q3 2026, a significant improvement from a $367.6 million loss a year earlier, driven by tariff refunds, productivity gains, and cost reductions. Net revenues slightly declined by 1.4% to ...
Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced its participation in several major healthcare conferences from November to December 2026. The company will engage in fireside chat...
Hormel Foods Corporation will release its fourth-quarter and full-year 2026 financial results on December 3, 2026, before market open. The company will also hold a webcast and conference call at 8 a.m. CT to discuss the results and provide an outlook...
